Sparks commentary - IRLAB Therapeutics

Healthcare

Sparks - IRLAB Therapeutics

More on this equity
IRLAB (OMX: IRLAB-A) – last patient completes treatment in pirepemat trial
Published by Arron Aatkar, PhD

IRLAB has announced that all patients enrolled in the REACT-PD trial have completed treatment and had their final follow-up visit. This Phase IIb study is evaluating IRLAB’s prefrontal cortex enhancer, pirepemat, as a potential therapy to improve balance and reduce falls in Parkinson’s disease patients. Top-line results are due to be reported in Q125, consistent with prior guided timelines for the trial.

Latest

TMT | Comment

Pinewood (LSE: PINE) buys Seez

Industrials | Comment

Metlen (ASE: MYTIL) FY24 Results

Healthcare | Comment

GSK’s (LSE: GSK) five-in-one vaccine approved by the FDA

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free